1 / 21

Effect of Litigation on Stent Markets

Agenda. General Significance of TopicEffects of winning/losing on a companyMonetary effects from trialThree Example CasesBoston Scientific vs. Guidant CorpBoston Scientific vs. MedtronicJohnson

kioko
Download Presentation

Effect of Litigation on Stent Markets

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    1. Effect of Litigation on Stent Markets Hannah Yun Marketing Group March 13, 2003

    2. Agenda General Significance of Topic Effects of winning/losing on a company Monetary effects from trial Three Example Cases Boston Scientific vs. Guidant Corp Boston Scientific vs. Medtronic Johnson & Johnson vs. Boston Scientific Cost Analysis Why Do Companies Continue to Bring Cases to Trial?

    3. Why is Litigation an Issue? Must consider suits when marketing a new product Monetary effects Damages Legal fees Outcome of a case affects a company’s Direction Product development Ability to get to the market on time While the damage awards can be huge, the process of filing and defending patents is expensive. A typical case costs each party $1.5 million and often takes two years to get to a judgment — not including the inevitable appeal, McDaniel said.While the damage awards can be huge, the process of filing and defending patents is expensive. A typical case costs each party $1.5 million and often takes two years to get to a judgment — not including the inevitable appeal, McDaniel said.

    4. 1997: Angiotech issues co-exclusive license to use paclitaxel to Boston Scientific and Cook Group August 2001: Guidant & Cook Group agree to work together to develop and market a paclitaxel-coated heart stent Challenged by Boston Scientific June 2002: U.S. District Judge calls Guidant’s agreement with Cook “unlawful” and “a sham” How could Guidant get around this ruling?

More Related